Impact of serum omentin-1 levels on cardiac prognosis in patients with heart failure

Table 1 Baseline clinical characteristics

	Control (n=20)	Heart failure (n=136)	P value
Age, years	65 ± 16	72 ± 12	0.034
Male, n (%)	11 (55)	76 (56)	0.941
NYHA functional class, II/III/IV	-	71/46/19	-
Etiology, n (%)			-
Dilated cardiomyopathy	-	29 (21)
Valvular heart disease	-	38 (28)
Ischemic heart disease	-	30 (22)
Hypertensive heart disease	-	14 (10)
Hypertrophic cardiomyopathy	-	9 (7)
Others	-	16 (12)
Presentation profile
Systolic pressure, mmHg	119 ± 22	117 ± 18	0.772
Diastolic pressure, mmHg	77 ± 10	74 ± 10	0.209
Body mass index, kg/m²	23.3 ± 3.4	21.7 ± 3.9	0.049
eGFR, ml/min/1.73m²	70 ± 24	62 ± 26	0.197
Blood biomarkers
Albumin, g/dl	3.8 ± 0.5	3.5 ± 0.6	0.091
Total cholesterol, mg/dl	185 ± 34	166 ± 39	0.042
Triglyceride, mg/dl	143 ± 96	91 ± 47	<0.001
LDLc, mg/dl	111 ± 28	100 ± 37	0.213
HDLc, mg/dl	52 ± 15	53 ± 23	0.831
hsCRP, mg/dl (IQR)	0.121 (0.040-0.551)	0.198 (0.064-0.606)	0.279
BNP, pg/ml (IQR)	82 (50–152)	484 (215–1251)	<0.001
Omentin-1, ng/ml (IQR)	494 (351–630)	305 (35–473)	0.035
Echocardiographic data
LV end-diastolic diameter, mm	53 ± 8	55 ± 11	0.438
LV ejection fraction, %	65 ± 9	50 ± 18	<0.001
Medications, n (%)
ACE inhibitors and/or ARBs	15 (75)	102 (75)	0.999
β blockers	15 (75)	103 (76)	0.943
Statins	10 (50)	51 (38)	0.321
Ca channel blockers	5 (25)	37 (27)	0.778

Data are presented as mean±SD or % unless otherwise indicated; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BNP, brain natriuretic peptide; BUN, Blood urea nitrogen; eGFR, estimated glomerular filtration rate; HDLc, high density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; IQR, interquartile range; LDLc, low density lipoprotein cholesterol; LV, left ventricular; NYHA, New York Heart Association.

ISSN: 1475-2840